-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Personalized Medicine are studying a rare genetic disorder, familial adenomatous polyposis (FAP), for potential ways to prevent colorectal cancer in the general population , making it in an earlier treatable stag.
"Colorectal cancer is the third most common cancer in the United States, and the precursor to this cancer is the development of colon polyps," said Niloy Jewel Samadder, MD, a gastroenterologist at the Mayo Clinic in Arizon.
"The biological pathways for the development of polyps and colon cancer in patients with FAP are the same as in the general population," said D.
The researchers found that using the drug erlotinib, which blocks a specific cancer pathway called EFGR, reduced the number of polyps that formed in the guts of FAP patients by 30 percen.
